Abstract 30P
Background
Colorectal cancer (CRC) stands as a formidable contributor to cancer-related mortality globally, motivating ongoing efforts to enhance diagnostic and therapeutic strategies. Among emerging candidates, Suppressor of Cytokine Signalling 6 (SOCS6) has garnered attention for its potential implications in tumorigenesis, including CRC. Previously, dot blot technique revealed that SOCS6 binds to multiple candidates, including the erythropoietin receptor (EPOR), which is known to have role in cancer development. Therefore, SOCS6 could regulate the expression of EPOR to facilitate CRC progression. However, the differential expression patterns of SOCS6 and its correlation with EPOR in CRC is not well elucidated. This study aims to correlate expression levels of SOCS6 with the clinical outcomes using immunohistochemistry and to investigate the functional role of SOCS6 along with its correlation with EPOR in CRC.
Methods
Immunohistochemical staining was performed on a total of 80 formalin-fixed, paraffin-embedded CRC specimens, including 70 cancerous and 10 normal tissues, to unveil SOCS6 expression patterns. Moreover, to investigate the role, SOCS6 was silenced using siRNA and functional assays (cell proliferation, and wound healing) were performed in CRC cell lines (HT-29 and COLO-320DM). Also, qRT-PCR, and western blot were conducted to determine the correlation between SOCS6 and EPOR.
Results
Immunohistochemistry revealed a reduction in SOCS6 expression in CRC specimens compared to the normal tissue, yet not significantly associated with tumour stage or grade. Molecular investigations elucidated significant increase in cell proliferation in SOCS6 silenced HT-29 and COLO-320DM cells, demonstrating its tumor suppressive function. In terms of wound healing assay, the gap closure was significantly higher only in SOCS6 silenced COLO-320DM cells. In addition, silencing SOCS6 resulted in the upregulation of EPOR in COLO-320DM cells, however EPOR levels were reduced in HT-29 cells.
Conclusions
Our current findings suggest the tumour suppressive role of SOCS6 in CRC, with the potential to serve as a diagnostic and therapeutic marker.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Sultan Qaboos University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
25P - Feasibility of digital spatial profiling as a diagnostic: Comparison to immunohistochemistry (IHC)
Presenter: Hannah Hibbs
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Predictive biomarker discovery for ICI treatment response in metastatic MMRd endometrial cancer through deep proteomic profiling of FFPE tissue samples
Presenter: Juan Francisco Grau-Béjar
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Analytical validation of a small amplicon NGS panel for MSI detection
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Clinical significance of TROP2 expression in lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - PTEN/CREBBP/NOTCH1 co-alterations with TP53/RB1 define molecular subtypes associated with primary therapy resistance in small cell lung cancer (SCLC)
Presenter: Louisa Hempel
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Adult granulosa cell tumours of ovary: Analysis of 227 non-recurrent and recurrent cases
Presenter: Jan Hojný
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Clinical evaluation cancer testis antigen 45 (CT45) expression in ovarian cancer
Presenter: Harshita Dubey
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Molecular-genetic concordance of the primary tumor and brain metastases of colorectal cancer (GENCONCOR-1)
Presenter: David Halafyan
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - A prognostic signature to predict recurrence in patients with residual disease in triple-negative breast cancer: NACATRINE trial
Presenter: Ana Julia de Freitas
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Whole exome sequencing reveals high frequency of Notch pathway mutations in Indian breast cancer cases
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract